Showing Results for: “diabetes exercise”

The American Diabetes Association ® (ADA) is excited to offer Project Power for adults again this year, a no-cost lifestyle change program to empower people to reduce their risk for or manage and thrive with type 2 diabetes. Project Power is tailored for adults, ages 18+ with prediabetes, type 2 diabetes or who are at high-risk for diabetes. Participants receive a personalized program that combines health coaching, an evidence-based curriculum, and a gamified experience to help learn about disease risk reduction. “We’re on a mission to tackle the diabetes epidemic, one person and community at

First-of-Its-Kind Study Shows Fenofibrate Reduces Eye Disease Progression by 27% Today, findings from the Lowering Events in Non-proliferative retinopathy in Scotland (LENS) Trial revealed that fenofibrate, a medication used for many years to reduce blood fat levels, significantly reduces the progression of diabetic retinopathy, a diabetes-related eye disease. Delivered by Oxford Population Health, this is the first large-scale trial specifically designed to investigate the effect of this drug on eye outcomes in people with early diabetic retinopathy. The results were presented at a symposium

Data Indicates How Changes to Public Health Recommendation on BPA has Potential to Decrease Diabetes Risk A new study reveals the benefits of reducing exposure to a common chemical for reducing the risk of diabetes. The findings are the first to provide evidence that BPA administration may increase type 2 diabetes risk and were presented as an Oral Presentation - Presidents' Select Abstract as well as a Symposium at the 84 th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Bisphenol A (BPA) is an industrial chemical used to make polycarbonate plastic and epoxy

Novel Drugs Demonstrate Benefits of Once Weekly Drugs for Weight Loss and Glycemic and Blood Pressure Control Findings from three studies showcase new data on the latest developments in drug therapy innovations to treat obesity including new insights on GLP-1 (Glucagon-like peptide-1) receptor agonists. The data was presented as a late-breaking poster and oral presentations, respectively at the American Diabetes Association® (ADA) 84th Scientific Sessions in Orlando, FL. The studies are part of a host of research and development driven by interest in new GLP-1 drugs and concerns about obesity

The American Diabetes Association ® (ADA) is proud to announce that its strong financial health and ongoing accountability and transparency have earned it a Four-Star Rating from Charity Navigator. This rating designates the ADA as an official “Give with Confidence” charity, indicating that the ADA is using its donations effectively based on Charity Navigator’s criteria. Charity Navigator is America’s largest and most utilized independent charity evaluator. Since 2001, the organization has been an unbiased and trusted source of information for more than 11 million donors annually. Charity

Findings Indicate Improvements in Mental and Physical Health as well as a Reduction in Healthcare Costs For People Living with Type 1 Diabetes Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented today at the 83rd Scientific Sessions of the American Diabetes Association ® (ADA) in San Diego, CA. As the number of diabetes cases continues to rise, addressing mental health challenges is a critical element in helping individuals with diabetes manage their care plan. Diabetes distress (DD) for

“ The American Diabetes Association ® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. We applaud Eli Lilly for taking the important step to limit cost-sharing for its insulin, and we encourage other insulin manufacturers to do the same. While we have been able to help achieve significant progress on the issue of insulin affordability, including Medicare’s new out-of-pocket cost cap on insulin, state copay caps, and patient assistance developments from insulin manufacturers, we know that

New guidelines include most substantial changes since standards first introduced, including easier documentation of services and clarity around reporting outcomes New updates to the National Standards for Diabetes Self-Management Education and Support (National Standards) call for addressing health equity by improving access to diabetes self-management education and support (DSMES) services, a renewed focus on increasing and maintaining person-centered care and reducing administrative burden. Issued by the American Diabetes Association ® (ADA) and the Association of Diabetes Care & Education

American Diabetes Association and DaVita launch a digital experience with resources for preventing and managing diabetes-related kidney complications The American Diabetes Association ® (ADA), along with DaVita, are excited to announce the launch of an interactive digital experience aimed at helping those living with diabetes prevent and manage kidney disease. Diabetes affects one in seven adults in the U.S.—and is the number one cause of chronic kidney disease (CKD). Committed to providing the education and resources needed to combat diabetes-related health complications, the ADA recently

The American Diabetes Association ® (ADA), the leading global diabetes research, advocacy, and education organization, applauds U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME) for introducing legislation today during a joint press conference on Capitol Hill in Washington, D.C., which aims to make insulin more affordable for millions of Americans with diabetes who rely on the drug to live. The bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act includes important reforms to reduce the price of insulin by incentivizing lower list prices and